Latest Conference Articles

March 2nd 2019, 6:43pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Carla Casulo, MD, discusses several different factors that can help predict outcomes in patients with follicular lymphoma.

March 2nd 2019, 3:46am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Real-world data on the use of chimeric antigen receptor T-cell therapy in large B-cell lymphoma bear out the pivotal results from ZUMA-1 and demonstrate not only that the treatment approach is here, but also that it’s time to address issues of efficacy, safety, cost, and moving this approach into earlier lines of therapy.

March 2nd 2019, 3:23am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jorge E. Cortes, MD, discusses the current treatment options for patients with acute myeloid leukemia, including the use of quizartinib in patients with FLT3 mutations, as well as data from the QuANTUM-R trial.

March 2nd 2019, 1:03am

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Naval G. Daver, MD, discusses the role of minimal residual disease assessment in the treatment of patients with hematologic malignancies.

March 1st 2019, 11:53pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Jae H. Park, MD, discusses a particular challenge he sees in using CAR T-cell therapies in patients with acute myeloid leukemia.

March 1st 2019, 11:47pm

PER® Congress on Hematologic Malignancies (Winter Hematology®)

B-cell maturation antigen-specific chimeric antigen receptor T-cell therapy is delivering impressive results in multiple myeloma, demonstrating durable responses and acceptable toxicities.

February 28th 2019, 11:32pm

AACR Annual Meeting

Pre-existing cardiovascular disease was associated with an increased mortality risk during the first 6 months of abiraterone acetate treatment in patients with advanced prostate cancer.

February 28th 2019, 3:24am

AACR Annual Meeting

Many younger patients see more than one doctor and face misdiagnoses before being given a diagnosis of colorectal cancer.

February 28th 2019, 3:09am

AACR Annual Meeting

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non–small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

February 28th 2019, 3:07am

AACR Annual Meeting

Select patients with melanoma who consume a diet rich in fiber could see an improved response to treatment with immunotherapy.

February 25th 2019, 4:34am

Transplantation and Cellular Therapy Meetings

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

February 25th 2019, 2:53am

Transplantation and Cellular Therapy Meetings

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.

February 25th 2019, 2:12am

Transplantation and Cellular Therapy Meetings

Paul J. Shaughnessy, MD, discusses stem cell mobilization in patients with lymphomas.

February 25th 2019, 1:54am

Transplantation and Cellular Therapy Meetings

Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1

February 24th 2019, 1:18am

Transplantation and Cellular Therapy Meetings

Premal Lulla, MD, discusses the need for cellular therapies for patients with leukemia after transplant.

February 23rd 2019, 10:27pm

Transplantation and Cellular Therapy Meetings

Sergio A. Giralt, MD, discusses the role of allogeneic hematopoietic cell therapy in patients with multiple myeloma.

February 23rd 2019, 10:25pm

Transplantation and Cellular Therapy Meetings

Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.

February 23rd 2019, 9:49pm

Transplantation and Cellular Therapy Meetings

Christopher E. Dandoy, MD, MSc, discussed how higher levels of soluble suppression of tumorigenicity-2 and soluble terminal complement complex were associated with high-risk thrombotic microangiopathy, a severe complication related to stem cell transplantation.

February 23rd 2019, 2:33am

Transplantation and Cellular Therapy Meetings

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

February 23rd 2019, 12:46am

Transplantation and Cellular Therapy Meetings

Richard E. Champlin, MD, a professor of medicine at MD Anderson Cancer Center, discusses the association seen between the Endothelial Activation and Stress Index (EASIX) and fluid overload and survival in patients who underwent an allogenic stem cell transplantation.